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Dr Craig R. Smith (New York, NY). First, I thank you for send-
ing me a manuscript a couple of weeks ago. That shows a high level
of organization.
It’s nice to bring compounds like this before us. It takes a lot of
courage to try to do something like this when you know that this
might work out very well but then 25 years from now somebody
will publish a paper in the New England Journal of Medicine show-
ing 100,000 patients in a meta-analysis with 0.2% increase in cre-
atinine with a P value of .00001, and you’ll be out of business.
You picked 2 drugs that are extremely potent as antikallikrein
agents. In the Ki tables, I gather you assume that the plasma Ki com-
pletely summarizes the drugs’ antifibrinolytic action. I’m not sure
that’s true, but perhaps it is. There may be other ways to directly
assess antifibrinolysis, which has usually been assumed to be the
main mechanism by which aprotinin reduces blood loss and has188 The Journal of Thoracic and Cardiovascular Surgspawned other antifibrinolytic agents, which you’re all familiar
with, tranexamic acid and aminocaproic acid. Can you tell us any-
thing about how your agents behave as antifibrinolytics, either with
plasma Ki or some more elaborate assessment of antifibrinolytic
activity?
Dr Szabo´. I only showed some examples of Ki values on human
serum proteases. And it’s true that plasmin activation is not the only
one mechanism in fibrinolysis.
We have also additional data where we additionally investigated
the effects of these new compounds on fibrinolysis. And we have
found, in terms of fibrinolysis, not really much difference from
aprotinin; but then the aim of designing this model was to have
something similar to aprotinin. What we did, and that was impor-
tant to show, was try to add some other protease inhibitory actions
in terms of improved anticoagulatory properties. As we showed in
terms of factors Xa and XIa, there are considerable gulatory prop-
erties in these drugs.
Dr Smith. That’s clearly an advantage of these drugs. But you
didn’t test their antifibrinolytic activity against tranexamic acid or
other agents that are more specific?
Dr Szabo´. No, just against aprotinin.
Dr Smith. Regarding my second question, I notice that you dis-
cussed celite in your manuscript. I’m still surprised that you chose
to use a celite activator, knowing it sets you up for questions from
somebody like me who will ask you about the celite-aprotinin inter-
action.
You assume, I gather, that the equivalence of ACTs in all the
groups means that there was no artificial elevation of ACT by apro-
tinin, but can you tell us what the heparin doses were?
Dr Szabo´. Well, in terms of celite ACT, I think that is an impor-
tant issue in terms of management in the human situation. In our
study, we could not document what we know from the clinical
arena, that aprotinin artificially prolongs ACTs. Nevertheless, we
used the normal human dose. It seems that dogs are more sensitive
to heparin, so we have much higher ACT values, longer than 1000
or 1500 seconds, and that might be why we could not document the
artificial prolongation of ACT in response to aprotinin. What we
saw is that the new compounds also prolonged PTT, which was
not prolonged by aprotinin. So we speculate that we have here
a true prolongation of blood coagulation, and not an artificial situ-
ation, also in terms of ACT. This would imply that it in a human
situation we would not need higher heparin doses for the patients.
Dr Smith. Since you didn’t actually answer the question about
what the heparin doses were in the different groups, I’ll just move
beyond that. But another way to look at that would be to look for
evidence of thrombin generation in all the groups, for a host of rea-
sons but one of them being to ensure that your ACTs were not in-
accurately reflecting the degree of anticoagulation.
Dr Pirooz Eghtesady (Cincinnati, Ohio). Did you look at renal
function or renal clearance of these drugs? Did you look at kidney
function?
Dr Szabo´. We have no data in this model about renal function.
The only related measurement was the urinary output during CPB,
primary with the aim of volume management, and we saw no dif-
ferences between the groups.ery c January 2010
